Literature DB >> 11222376

A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability.

M Clauss1, C Sunderkötter, B Sveinbjörnsson, S Hippenstiel, A Willuweit, M Marino, E Haas, R Seljelid, P Scheurich, N Suttorp, M Grell, W Risau.   

Abstract

Vascular endothelial growth factor (VEGF) induces both angiogenesis and an increase in vascular permeability, 2 processes that are considered to be important for both tumor growth and the delivery of drugs to the site of tumors. This study demonstrates that transmembrane expression of tumor necrosis factor (tmTNF) is up-regulated in the endothelium of a murine methylcholanthrene (meth A)-induced sarcoma in comparison to the adjacent normal dermal vasculature and is also present on cultivated human endothelial cells. It is further shown that tmTNF is required for VEGF-mediated endothelial hyperpermeability in vitro and in vivo. This permissive activity of TNF appears to be selective, because anti-TNF antibodies ablated the VEGF-induced permeability but not proliferation of cultivated human endothelial cells. Furthermore, tnf gene-deficient mice show no obvious defects in vascularization and develop normally but failed to respond to administration of VEGF with an increase in vascular permeability. Subsequent studies indicated that the tmTNF and VEGF signaling pathways converge at the level of a secondary messenger, the "stress-activated protein kinase-2" (SAPK-2)/p38: (1) up-regulated endothelial expression of tmTNF resulted in the continuous activation of SAPK-2/p38 in vitro, and (2) an inhibitor of SAPK-2/p38 activation abolished the vascular permeability activity of VEGF in vivo. In conclusion, the study's finding that continuous autocrine signaling by tmTNF sensitizes endothelial cells to respond to VEGF by increasing their vascular permeability provides new therapeutic concepts for manipulating vascular hyperpermeability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222376     DOI: 10.1182/blood.v97.5.1321

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

Authors:  Ferdy J Lejeune
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  [Leukocytoclastic vasculitis].

Authors:  C Sunderkötter; J Roth; G Bonsmann
Journal:  Hautarzt       Date:  2004-08       Impact factor: 0.751

Review 3.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

4.  Beneficial dysregulation of the time course of inflammatory mediators in lipopolysaccharide-induced tumor necrosis factor alpha factor-deficient mice.

Authors:  Sreedevi Srinivasan; Susan E Leeman; Salomon Amar
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

5.  Soluble thrombomodulin reduces inflammation and prevents microalbuminuria induced by chronic endothelial activation in transgenic mice.

Authors:  Gangaraju Rajashekhar; Akanksha Gupta; Abby Marin; Jessica Friedrich; Antje Willuweit; David T Berg; Martin S Cramer; George E Sandusky; Timothy A Sutton; David P Basile; Brian W Grinnell; Matthias Clauss
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-30

6.  Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation.

Authors:  Linden Ann Green; Chul Kim; Samir K Gupta; Gangaraju Rajashekhar; Jalees Rehman; Matthias Clauss
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

7.  Tumor necrosis factor alpha and gamma interferon, but not hemorrhage or pathogen burden, dictate levels of protective fibrin deposition during infection.

Authors:  Isis K Mullarky; Frank M Szaba; Kiera N Berggren; Lawrence W Kummer; Lindsey B Wilhelm; Michelle A Parent; Lawrence L Johnson; Stephen T Smiley
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

Review 8.  Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Authors:  Bruce C Baguley; Dietmar W Siemann
Journal:  Expert Opin Investig Drugs       Date:  2010-11       Impact factor: 6.206

Review 9.  Vascular endothelial growth factors and vascular permeability.

Authors:  David O Bates
Journal:  Cardiovasc Res       Date:  2010-04-16       Impact factor: 10.787

10.  Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin.

Authors:  Angeliki Xagorari; Charis Roussos; Andreas Papapetropoulos
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.